Novo Integrated Sciences, Inc. NVOS
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $730.0K
- P/E
- 0.0×
Follow NVOS
Growth Flags
show if company had growth for consecutive years
| Aug '24 | May '24 | Feb '24 | Nov '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 98.44 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.39 | 1.45 | 0.81 | 1.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.58) | (29.82) | (6.49) | (9.33) | |
P/B ratio |
0.36 | 2.03 | 0.51 | 0.86 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 802.86 | |
EV/Sales |
0.41 | 1.42 | 0.84 | 1.50 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.08) | (4.03) | (2.33) | (4.74) | |
EV/FCF |
(1.06) | (3.99) | (2.31) | (4.68) | |
Quick Ratio |
0.27 | 0.21 | 0.39 | 0.49 | |
Current Ratio |
0.37 | 0.27 | 0.50 | 0.62 | |
Net Debt/EBITDA |
(0.35) | (0.50) | 2.94 | 0.34 | |
Debt/Assets |
3.33% | 3.02% | 3.07% | 2.88% | |
Debt/Equity |
0.07 | 0.11 | 0.05 | 0.05 | |
Asset Turnover |
0.39 | 0.38 | 0.38 | 0.35 | |
Operating CF/Net income |
(0.11) | 0.05 | 0.62 | 0.46 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
81.60% | 108.41% | 90.33% | 135.22% | |
Intangible Assets out of Total Assets |
0.62 | 0.63 | 0.65 | 0.62 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 30.72% | |
Graham Net Nets |
(2.32) | (0.99) | (0.72) | (0.36) | |
Graham Number |
0.00 | 0.00 | 0.42 | 0.00 | |
Earnings Yield |
(300.00%) | (60.34%) | 1.02% | (36.13%) | |
Free Cash Flow Yield |
(97.99%) | (24.48%) | (44.98%) | (20.75%) | |
Revenue per Share |
0.17 | 0.17 | 0.18 | 0.23 | |
Operating CF per Share |
(0.03) | (0.04) | (0.10) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.04) | (0.10) | (0.13) | |
Cash per Share |
0.05 | 0.08 | 0.04 | 0.10 | |
Shareholders Equity per Share |
0.81 | 0.52 | 1.24 | 1.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.81 | 0.52 | 1.24 | 1.39 | |
Free Cash Flow |
(0.55) | (0.66) | (1.71) | (2.15) | |
Working Capital |
(9.16) | (16.52) | (4.94) | (4.11) | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
(12.11) | (19.50) | (8.04) | (7.15) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
162.35% | (435.99%) | (86.61%) | (120.28%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.84 | 2.83 | 2.59 | 2.85 | |
Average Payables |
3.37 | 2.90 | 2.11 | 2.74 | |
Average Inventory |
1.05 | 1.03 | 0.94 | 1.14 | |
Average Assets |
33.85 | 35.54 | 35.72 | 37.50 | |
Average Common Equity |
19.56 | 17.98 | 24.43 | 21.98 |
Columns are period end dates